Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70483 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2025. Written by Takashi Kumada and 6 co-authors. Institution: Department of Nursing, Faculty of Nursing, Gifu Kyoritsu University, Gifu, Japan. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Chronic, RNA, Viral. Cited 2 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Roche Diagnostics Japan, Roche Diagnostics.
Abstract (original language)
Background
Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B (CHB) remain at risk of hepatocellular carcinoma (HCC). Novel covalently closed circular DNA activity biomarkers may improve risk stratification.
Aims
To comprehensively assess the association between serum HBV RNA and hepatitis B core‐related antigen (HBcrAg) levels, measured upon achieving undetectable HBV DNA levels, and subsequent HCC development in NA‐treated patients with CHB.
Methods
We retrospectively analysed 311 patients with CHB who achieved undetectable HBV DNA levels during NA therapy between 2000 and 2024. Serum HBV RNA (≥ 10 copies/mL) and HBcrAg (≥ 2.1 log U/mL) were measured in stored samples collected when HBV DNA first became undetectable. Cox regression analysis was performed to identify the factors associated with HCC development.
Results
During a median follow‐up of 11.0 years, 31 (10.0%) patients developed HCC. At viral suppression, 132 (42.4%) patients had HBV RNA ≥ 10 copies/mL. HCC incidence was significantly higher in patients with quantifiable HBV RNA than in those with unquantifiable HBV RNA (15‐year incidence, 17.8% vs. 8.8%, p = 0.026). Quantifiable HBV RNA independently predicted HCC (adjusted hazard ratio [aHR], 3.313; 95% confidence interval [CI]: 1.154–9.507; p = 0.026). HBcrAg showed no association (aHR, 0.821; 95% CI: 0.253–2.669; p = 0.743). Patients with quantifiable HBV RNA and albumin‐bilirubin score ≥ −2.60 had the highest risk (5‐year incidence: 15.8%).
Conclusions
HBV RNA levels at viral suppression predict HCC development in NA‐treated patients with CHB, outperforming HBcrAg. Incorporating HBV RNA assessment can improve risk‐stratified HCC surveillance strategies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Nursing, Faculty of Nursing, Gifu Kyoritsu University, Gifu, Japan.
- Department of Epidemiology, Infectious Disease Control, and Prevention, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan.
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
ORCID profiles: Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Yuichi Koshiyama, Takanori Ito, Tomoyuki Akita, Junko Tanaka
Funding
- Roche Diagnostics Japan
- Roche Diagnostics
Cite
APA
Kumada, T., Toyoda, H., Yasuda, S., Koshiyama, Y., Ito, T., Akita, T., & Tanaka, J. (2025). Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70483
Vancouver
Kumada T, Toyoda H, Yasuda S, Koshiyama Y, Ito T, Akita T, et al. Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70483
BibTeX
@article{Kumada2025,
author = {Kumada, Takashi and Toyoda, Hidenori and Yasuda, Satoshi and Koshiyama, Yuichi and Ito, Takanori and Akita, Tomoyuki and Tanaka, Junko},
title = {Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70483}
}
EUVIMED